337 reports of this reaction
3.7% of all FLECAINIDE ACETATE reports
#1 most reported adverse reaction
ATRIAL FIBRILLATION is the #1 most commonly reported adverse reaction for FLECAINIDE ACETATE, manufactured by ANI Pharmaceuticals, Inc.. There are 337 FDA adverse event reports linking FLECAINIDE ACETATE to ATRIAL FIBRILLATION. This represents approximately 3.7% of all 9,204 adverse event reports for this drug.
Patients taking FLECAINIDE ACETATE who experience atrial fibrillation should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ATRIAL FIBRILLATION is moderately reported among FLECAINIDE ACETATE users, representing a notable but not dominant share of adverse events.
In addition to atrial fibrillation, the following adverse reactions have been reported for FLECAINIDE ACETATE:
The following drugs have also been linked to atrial fibrillation in FDA adverse event reports:
ATRIAL FIBRILLATION has been reported as an adverse event in 337 FDA reports for FLECAINIDE ACETATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
ATRIAL FIBRILLATION accounts for approximately 3.7% of all adverse event reports for FLECAINIDE ACETATE, making it one of the most commonly reported side effect.
If you experience atrial fibrillation while taking FLECAINIDE ACETATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.